

Appendix 7: Participant Data

| Participant Screening Number | Participant Randomisation Number | Sex | Age | Treatment | Visit 1/2 | | | Visit 3 | | | Visit 4 | | | Visit 5 | | | Visit 6 | | | Did the participant meet the primary endpoint? | Did the participant meet the secondary endpoint? | |
|------------------------------|----------------------------------|-----|-----|---------------|----------------------------------|------------|-----|--------------------|------------|-----|--------------------|------------|-----|--------------------|------------|-----|--------------------|------------|-----|--|--|--------------------|
| | | | | | CHILD – PUCH Class | Meld Score | WCC | CHILD – PUCH Class | Meld Score | WCC | CHILD – PUCH Class | Meld Score | WCC | CHILD – PUCH Class | Meld Score | WCC | CHILD – PUCH Class | Meld Score | WCC | | | CHILD – PUCH Class |
| JB0001 | JB0001 | F | 54 | VSL#3 | Failed screening | | | | | | | | | | | | | | | No | No | |
| MS0002 | MS0002 | M | 65 | VSL#3 | C | 15 | 0.2 | C | 16 | 0.3 | | | | | | | | | | | Yes- death from liver failure | |
| RW0003 | RW0003 | F | 71 | Cotrimoxazole | B | 10 | 0.2 | B | 8 | 0.2 | B | 8 | 0.1 | B | 8 | 0.1 | | | | No | No | |
| PM0004 | N/A | M | 51 | N/A | Failed screening | | | | | | | | | | | | | | | No | No | |
| MA0005 | MA0004 | M | 47 | Placebo | B | 17 | 0.2 | | | | | | | | | | | | | | Yes-hospital admission for liver related complications; admission for encephalopathy (intracerebral haemorrhage) and ascites | No |
| WH0006 | N/A | F | 67 | N/A | Failed screening | | | | | | | | | | | | | | | No | No | |
| SK0007 | N/A | F | 63 | N/A | Failed screening | | | | | | | | | | | | | | | No | No | |
| SK0008 | SK0005 | M | 70 | Cotrimoxazole | B | 12 | 0.2 | B | 13 | 0.1 | B | 14 | 0.1 | | | | | | | No | Yes- patient diagnosed with C difficile infection and pleural effusion | |
| TH0009 | N/A | M | 62 | N/A | Failed screening | | | | | | | | | | | | | | | No | No | |
| DB0010 | N/A | F | 59 | N/A | Unable to proceed past screening | | | | | | | | | | | | | | | No | No | |
| AD0011 | AD0006 | F | 37 | Placebo | C | 16 | 0.2 | C | 13 | 0.2 | C | 8 | 0.2 | C | 6 | N/D | | | | No | No | |
| DC0012 | DC0008 | M | 49 | VSL#3 | B | 11 | 0.3 | B | 9 | 0.4 | B | 11 | 0.2 | B | 10 | 0.3 | | | | No | No | |
| TD0013 | TD0007 | M | 53 | Placebo | B | 9 | 0.4 | B | 7 | N/D | A | 7 | N/D | | | | | | | No | No | |
| JH0014 | JH0009 | F | 54 | VSL#3 | A | 13 | 0.2 | A | 13 | 0.2 | A | 12 | 0.2 | | | | | | | Yes- hospital admission for liver related complication; admission for liver transplant | | |
| AW0025 | AW0010 | F | 50 | Placebo | C | 16 | 0.1 | C | UNK | 0.1 | | | | | | | | | | | Yes- hospital admission for liver related complication; admission for | |

Appendix 7: Participant Data

| | | | | | | | | | | | | | | |
|---------------|------------|---|----|-----|-----|-----|-----|--|--|--|--|--|---|----|
| | | | | | | | | | | | | | episode of malaena and haematemosis. Liver disease deterioration-for palliative care only | |
| LH0015 | N/A | M | 46 | N/A | N/A | N/A | N/D | | | | | | No | No |
| AM0016 | N/A | M | 57 | N/A | C | 15 | 0.3 | | | | | | No | No |